DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below 50-Day Moving Average of $0.89

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.89 and traded as low as $0.85. DBV Technologies shares last traded at $0.90, with a volume of 2,500 shares changing hands.Get DBV Technologies alerts:Analyst Ratings ChangesA number of equities research analysts have weighed in on DBVT shares. StockNews.com assumed coverage on shares of DBV Technologies in a report on Tuesday. They set a "hold" rating on the stock. JMP Securities boosted their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a "market outperform" rating in a research note on Wednesday, July 31st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of DBV Technologies in a report on Thursday, August 1st.Get Our Latest Stock Analysis on DBV TechnologiesDBV Technologies Stock PerformanceThe firm's fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.19. The stock has a market cap of $86.85 million, a P/E ratio of -1.07 and a beta of 0.68. DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period last year, the business posted ($0.26) earnings per share. Analysts predict that DBV Technologies S.A. will post -1.43 earnings per share for the current fiscal year. Institutional Trading of DBV TechnologiesAn institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,986 shares of the company's stock, valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company's stock. About DBV Technologies (Get Free Report)DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.Featured ArticlesFive stocks we like better than DBV TechnologiesWhat Are Dividend Contenders? Investing in Dividend ContendersAutodesk Stock: Analysts' Top AI Pick You Shouldn’t Overlook3 Must-Buy Warren Buffett Stocks for Volatile TimesHidden Opportunities in Li Auto’s Tough Quarter You Can’t MissThere Are Different Types of Stock To Invest InDon’t Overlook Campbell Soup: Here’s What Could Drive Its StockThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.→ I’m giving you the name of this investment for free (From Porter & Company) (Ad)Should you invest $1,000 in DBV Technologies right now?Before you consider DBV Technologies, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.While DBV Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here